RepRegen Ltd, a London, UK-based medical device company that develops products to repair and restore tissue, has raised £1.03m (approximately $1.6m) in funding.
The round was led by existing backer Imperial Innovations, with participation from Longbow Capital and other undisclosed investors.
The company intends to use the new capital to continue to advance its product pipeline including regulatory approvals, commercialization programs and preparation for relevant post market clinical studies.
RepRegen uses a repair and regeneration technology in two platforms, designed to mend and regrow tissue in vivo. The first platform is focused on bone and other hard tissue, whereas the second one is focused on muscle and other tissue.
After having received CE Marking approval, the company is now commercializing the first product of its hard tissue repair and regeneration platform – StronBone™ bone graft substitute bioactive glass with Strontium, which is targeted for orthopaedic (trauma and spine) and craniomaxillofacial applications. In the USA, the product has not yet been cleared by the FDA and can therefore only be used for investigational use.